InsiderTrades.com logo
Man who Predicted Trump 2016 Win: “Prepare for Election Meltdown”
From Paradigm Press   |   Ad
Former advisor to the CIA, the Pentagon and the White House Jim Rickards went on multiple TV news programs… A predicted Trump would win. You won’t believe what he’s predicting now.
Click here to see it because it’s a SHOCKER…
David Alan Campbell net worth and biography
  • LinkedIn
  • Phone
  • Email
  • Website

David Campbell Biography and Net Worth

Founder, President & CEO of Janux Therapeutics

David founded Janux in 2017 to develop tumor-specific cancer therapeutics in order to improve patient safety and efficacy for this important class of drugs. David brings more than 25 years of seasoned executive management, company creation, and successful partnering coupled with broad disease and drug development expertise to his role as Janux CEO. Prior to Janux, David served as CSO or CEO of multiple drug discovery and development companies that have created numerous clinical programs and partnerships with large pharma. These include Sitari (celiac disease) partnered with GSK, Afraxis (oncology) partnered with Genentech, and RQx (anti-bacterial) partnered with Genentech. Before that, David was Senior Vice President of Drug Discovery and Development at Phenomix, where he guided the discovery and development of clinical programs to treat diabetes and hepatitis C. Earlier in his career, David held positions of increasing responsibility in biotech at Affymax and large pharma at Bayer Pharmaceuticals. As director at Bayer, his group contributed to multiple clinical programs in oncology, obesity, and diabetes.

David earned a Ph.D. in organic chemistry from Cornell University and a B.S. in chemistry from Harvey Mudd College, and received post-doctoral training under then University of California, Berkeley professor: Dr. Peter Schultz.

What is David Alan Campbell's net worth?

The estimated net worth of David Alan Campbell is at least $15.78 million as of October 28th, 2024. Dr. Campbell owns 282,054 shares of Janux Therapeutics stock worth more than $15,780,921 as of October 30th. This net worth estimate does not reflect any other investments that Dr. Campbell may own. Additionally, Dr. Campbell receives an annual salary of $1,040,000.00 as Founder, President & CEO at Janux Therapeutics. Learn More about David Alan Campbell's net worth.

How old is David Alan Campbell?

Dr. Campbell is currently 64 years old. There are 5 older executives and no younger executives at Janux Therapeutics. Learn More on David Alan Campbell's age.

What is David Alan Campbell's salary?

As the Founder, President & CEO of Janux Therapeutics, Inc., Dr. Campbell earns $1,040,000.00 per year. Learn More on David Alan Campbell's salary.

How do I contact David Alan Campbell?

The corporate mailing address for Dr. Campbell and other Janux Therapeutics executives is , , . Janux Therapeutics can also be reached via phone at 858-751-4493 and via email at [email protected]. Learn More on David Alan Campbell's contact information.

Has David Alan Campbell been buying or selling shares of Janux Therapeutics?

During the last quarter, David Alan Campbell has sold $1,338,500.00 in shares of Janux Therapeutics stock. Most recently, David Alan Campbell sold 25,000 shares of the business's stock in a transaction on Monday, October 28th. The shares were sold at an average price of $53.54, for a transaction totalling $1,338,500.00. Following the completion of the sale, the chief executive officer now directly owns 282,054 shares of the company's stock, valued at $15,101,171.16. Learn More on David Alan Campbell's trading history.

Who are Janux Therapeutics' active insiders?

Janux Therapeutics' insider roster includes David Campbell (Founder, President & CEO), and Andrew Meyer (Chief Business Officer). Learn More on Janux Therapeutics' active insiders.

Are insiders buying or selling shares of Janux Therapeutics?

During the last year, Janux Therapeutics insiders bought shares 2 times. They purchased a total of 2,049,854 shares worth more than $58,688,642.98. During the last year, insiders at the sold shares 12 times. They sold a total of 3,420,610 shares worth more than $183,538,665.79. The most recent insider tranaction occured on October, 28th when CEO David Alan Campbell sold 25,000 shares worth more than $1,338,500.00. Insiders at Janux Therapeutics own 35.4% of the company. Learn More about insider trades at Janux Therapeutics.

Information on this page was last updated on 10/28/2024.

David Alan Campbell Insider Trading History at Janux Therapeutics

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
10/28/2024Sell25,000$53.54$1,338,500.00282,054View SEC Filing Icon  
9/27/2024Sell25,000$46.31$1,157,750.00307,054View SEC Filing Icon  
See Full Table

David Alan Campbell Buying and Selling Activity at Janux Therapeutics

This chart shows David Alan Campbell's buying and selling at Janux Therapeutics by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Janux Therapeutics Company Overview

Janux Therapeutics logo
Janux Therapeutics, Inc., a clinical stage biopharmaceutical company, develops immunotherapies based on Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr) platforms technology to treat patients suffering from cancer. The company's clinical candidates comprise JANX007, a prostate-specific membrane antigen or PSMA-TRACTr, which is in Phase 1 clinical trial in adults for the treatment of metastatic castration-resistant prostate cancer (mCRPC) and the vasculature of other tumors; and JANX008, an epidermal growth factor receptor or EGFR-TRACTr that is in Phase 1 clinical trial for the treatment of multiple solid cancers, including colorectal cancer, squamous cell carcinoma of the head and neck, non-small cell lung cancer, and renal cell carcinoma. Its development pipeline also consists of discovery stage products. The company has strategic research collaboration agreement with Merck Sharp & Dohme Corp. to develop TRACTr product candidates. Janux Therapeutics, Inc. was incorporated in 2017 and is headquartered in San Diego, California.
Read More

Today's Range

Now: $55.95
Low: $54.14
High: $56.55

50 Day Range

MA: $47.72
Low: $41.26
High: $55.95

2 Week Range

Now: $55.95
Low: $5.65
High: $65.60

Volume

529,481 shs

Average Volume

713,510 shs

Market Capitalization

$2.92 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

3.54
Man who Predicted Trump 2016 Win: “Prepare for Election Meltdown”
From Paradigm Press   |   Ad
Former advisor to the CIA, the Pentagon and the White House Jim Rickards went on multiple TV news programs… A predicted Trump would win. You won’t believe what he’s predicting now.
Click here to see it because it’s a SHOCKER…